Evidence map›Paper›PMID 34661014›Full record

ArticleACS omega2021

Visualized and Quantitative Conformational Analysis of Peptidomimetics.

Hajime Takashima, Atsushi Yoshimori, Eiji Honda, Tomonori Taguri, Jun Ozawa, Masaji Kasai, Satoshi Shuto, Dai Takehara

Open access · goldAbstract read
In one paragraph

Article in ACS omega, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Hajime TakashimaResearch and Development Department, PRISM BioLab Co., Ltd., C21F-4110, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan.ORCID https://orcid.org/0000-0002-7436-040X
Atsushi YoshimoriChemoinformatics & AI Research Group, Institute for Theoretical Medicine, Inc., BW3M-20B, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan.
Eiji HondaResearch and Development Department, PRISM BioLab Co., Ltd., C21F-4110, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan.
Tomonori TaguriResearch and Development Department, PRISM BioLab Co., Ltd., C21F-4110, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan.
Jun OzawaResearch and Development Department, PRISM BioLab Co., Ltd., C21F-4110, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan.
Masaji KasaiResearch and Development Department, PRISM BioLab Co., Ltd., C21F-4110, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan.
Satoshi ShutoFaculty of Pharmaceutical Science, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo, Hokkaido 060-0812, Japan.ORCID https://orcid.org/0000-0001-7850-8064
Dai TakeharaResearch and Development Department, PRISM BioLab Co., Ltd., C21F-4110, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan.
Prism Biolab Corporation (Japan) · JPHokkaido University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Protein-protein interactions (PPIs) are fundamentally important and challenging drug targets. Peptidomimetic molecules of various types have been developed to modulate PPIs. A particularly promising drug discovery strategy, structural peptidomimetics, was designed based on special mimicking of side-chain C

Identifiers

PMID34661014
PMCPMC8515614
OpenAlexW3202227096

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.